Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tolerance and Pharmacokinetics of Galliprant™ Administered Orally to Collies Homozygous for MDR1-1Δ.

Journal of veterinary pharmacology and therapeutics - 1 Sept 2021

Heit Mark C, Mealey Katrina L, King Stephen B

Abstract excerpt

The objectives of the study were to evaluate the pharmacokinetics and tolerance of grapiprant, a substrate of the human P-gp transporter, in collies homozygous for MDR1-1Δ when administered at the labeled dosage of 2 mg/kg once daily for 28 days. Twelve collie dogs with homozygous for MDR1-1Δ genotype from a commercial colony were used in the study, eight in the treated group and four as placebo-treated controls....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1
Share to Dogs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Tolerance

Share to Genotype

Share to Homozygote

Share to Mutation

Share to Sulfonylurea Compounds

Source

Open in PubMed Open full text

Identifiers

PMID: 34219249
DOI: 10.1111/jvp.12984
PMCID: PMC9292342

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tolerance and Pharmacokinetics of Galliprant™ Administered Orally to Collies Homozygous for MDR1-1Δ.PMID 34219249Read ↗

Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.Semantic proximity Read ↗

Use of 20% intravenous lipid emulsion for the treatment of loperamide toxicosis in a Collie homozygous for the ABCB1-1∆ mutation.Semantic proximity Read ↗

Therapeutic implications of the MDR‐1 geneSemantic proximity Read ↗

Implications of ABC transporters on the disposition of typical veterinary medicinal products.Semantic proximity Read ↗

Review of prevalence, genetic aspects and adverse effects of the mdr1-1Delta mutation in dogs.Semantic proximity Read ↗

The pharmacogenomics of P-glycoprotein and its role in veterinary medicine.Semantic proximity Read ↗

MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin.Semantic proximity Read ↗

Ivermectin toxicity in an Australian Shepherd dog with the MDR1 mutation associated with ivermectin sensitivity in Collies.Semantic proximity Read ↗

Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion.Semantic proximity Read ↗

The Effect of the Canine ABCB1-1Δ Mutation on Sedation after Intravenous Administration of Acepromazine.Semantic proximity Read ↗

Canine and feline P‐glycoprotein deficiency: What we know and where we need to goSemantic proximity Read ↗

Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.